Therapeutic Drug Monitoring of Antifungals in Intensive Care Units

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-01-01

Study Completion Date

2019-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Antifungals under- and over-dosing are frequently deplored in patients treated with antifungals and receiving recommended doses, mostly in critically-ill patients. This situation is well-described for antifungals from the azoles class mostly in patients with liver dysfunction or having concomitant drugs that may interact with azoles. This situation is less-described using echinocandins, although recent studies reported caspofungin underdosing for critically-ill patients. Considering that antifungals under-dosing was demonstrated to be associated with an increase in mortality, it is of utmost importance to analyse the relevance of therapeutic drug monitoring (TDM) for patients admitted in intensive care units (ICU). This will help to identify which patients are the more prone to antifungal under or over-dosing. Indeed, antifungals under-dosing may favour the development of clinical resistance to antifungals and increase mortality, whereas over-dosing may result in adverse events that may lead to treatment discontinuation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Therapeutic Drug Monitoring of Fluconazole in Critically Ill Patients

NCT04252027

Critically Ill Patients

COMPLETED

Screening Anti-Fungal Exposure in Intensive Care Units

NCT03136926

Antifungal Agents

UNKNOWN

Variability of Fluconazole Concentration in Critically Ill Patients

NCT02491151

Invasive Candidiasis

COMPLETED

De-escalation - Antifungal Treatment Immunocompromised Patients

NCT03774316

Invasive Fungal Disease Critical Illness

COMPLETED

Systemic Fungal Infections in ICU Patients

NCT03292224

Fungal Infection

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Intensive Care Unit Patients

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Antifungal treatment

Patients receiving antifungal treatment during their stay in Intensive Care Unit

Antifungal treatment

Intervention Type DRUG

Treatment by fluconazole, voriconazole,posaconazole or caspofungin during the patient stay in Intensive Care Unit

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Antifungal treatment

Treatment by fluconazole, voriconazole,posaconazole or caspofungin during the patient stay in Intensive Care Unit

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients who received antifungals including fluconazole, voriconazole, posaconazole, or caspofungin, during their ICU stay and had a Therapeutic Drug Monitoring (TDM)

Exclusion Criteria

* Patients without antifungal treatment
* Patients who received an antifungal combination
* Pediatric patients
* Patients who were not admitted in ICU
* Patients who did not have a TDM

Minimum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No